These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 32794199)

  • 1. Proteinase 3 Autoreactivity in Anti-Neutrophil Cytoplasmic Antibody-associated vasculitis-Immunological versus clinical features.
    Sharma RK; Lövström B; Gunnarsson I; Malmström V
    Scand J Immunol; 2020 Nov; 92(5):e12958. PubMed ID: 32794199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Difference in relapse-rate and clinical phenotype by autoantibody-subtype in Japanese patients with anti-neutrophil cytoplasmic antibody-associated vasculitis.
    Murosaki T; Sato T; Akiyama Y; Nagatani K; Minota S
    Mod Rheumatol; 2017 Jan; 27(1):95-101. PubMed ID: 27320904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An unusual presentation of propylthiouracil-induced anti-MPO and PR3 positive ANCA vasculitis with associated anti-GBM antibodies, IgA nephropathy and an IgG4 interstitial infiltrate: a case report.
    Galante JR; Daruwalla CP; Roberts ISD; Haynes R; Storey BC; Bottomley MJ
    BMC Nephrol; 2020 Jul; 21(1):295. PubMed ID: 32703233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical characteristics of patients with vasculitis positive for anti-neutrophil cytoplasmic antibody targeting both proteinase 3 and myeloperoxidase: a retrospective study.
    Kim SM; Choi SY; Kim SY; Kim J
    Rheumatol Int; 2019 Nov; 39(11):1919-1926. PubMed ID: 31552433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A population-based study showing better renal prognosis for proteinase 3 antineutrophil cytoplasmic antibody (ANCA)-associated nephritis versus myeloperoxidase ANCA-associated nephritis.
    Mohammad AJ; Segelmark M
    J Rheumatol; 2014 Jul; 41(7):1366-73. PubMed ID: 24882836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of positive anti-neutrophil cytoplasmic antibodies without evidence of anti-neutrophil cytoplasmic antibodies-associated vasculitis.
    Bornstein G; Ben-Zvi I; Furie N; Grossman C
    Int J Rheum Dis; 2019 May; 22(5):940-945. PubMed ID: 30729688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Personalized Medicine in ANCA-Associated Vasculitis ANCA Specificity as the Guide?
    Wallace ZS; Stone JH
    Front Immunol; 2019; 10():2855. PubMed ID: 31867013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HLA-DPB1 as a Risk Factor for Relapse in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Cohort Study.
    Hilhorst M; Arndt F; Joseph Kemna M; Wieczorek S; Donner Y; Wilde B; Thomas Epplen J; van Paassen P; Cohen Tervaert JW
    Arthritis Rheumatol; 2016 Jul; 68(7):1721-30. PubMed ID: 26866715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis.
    Lionaki S; Blyth ER; Hogan SL; Hu Y; Senior BA; Jennette CE; Nachman PH; Jennette JC; Falk RJ
    Arthritis Rheum; 2012 Oct; 64(10):3452-62. PubMed ID: 23023777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and immunological features of drug-induced and infection-induced proteinase 3-antineutrophil cytoplasmic antibodies and myeloperoxidase-antineutrophil cytoplasmic antibodies and vasculitis.
    Csernok E; Lamprecht P; Gross WL
    Curr Opin Rheumatol; 2010 Jan; 22(1):43-8. PubMed ID: 19770659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measuring Circulating Complement Activation Products in Myeloperoxidase- and Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Wu EY; McInnis EA; Boyer-Suavet S; Mendoza CE; Aybar LT; Kennedy KB; Poulton CJ; Henderson CD; Hu Y; Hogan SL; Hu P; Xiao H; Nachman PH; Jennette JC; Falk RJ; Bunch DO
    Arthritis Rheumatol; 2019 Nov; 71(11):1894-1903. PubMed ID: 31215772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual MPO/PR3 ANCA positivity and vasculitis: insights from a 7-cases study and an AI-powered literature review.
    Bettacchioli E; Foulquier JB; Chevet B; Cornec-Le Gall E; Hanrotel C; Lanfranco L; de Moreuil C; Lambert Y; Dueymes M; Foulquier N; Cornec D
    Rheumatology (Oxford); 2024 Sep; 63(9):2557-2568. PubMed ID: 38552316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease Activity, Antineutrophil Cytoplasmic Antibody Type, and Lipid Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Wallace ZS; Fu X; Liao K; Kallenberg CGM; Langford CA; Merkel PA; Monach P; Seo P; Specks U; Spiera R; St Clair EW; Zhang Y; Choi H; Stone JH
    Arthritis Rheumatol; 2019 Nov; 71(11):1879-1887. PubMed ID: 31162829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenesis of PR3-ANCA associated vasculitis.
    Kallenberg CG
    J Autoimmun; 2008; 30(1-2):29-36. PubMed ID: 18162369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Histological Subtyping of Immune Cell Infiltrates in MPO-ANCA and PR3-ANCA Glomerulonephritis.
    Hakroush S; Tampe D; Ströbel P; Korsten P; Tampe B
    Front Immunol; 2021; 12():737708. PubMed ID: 34759920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.
    Unizony S; Villarreal M; Miloslavsky EM; Lu N; Merkel PA; Spiera R; Seo P; Langford CA; Hoffman GS; Kallenberg CM; St Clair EW; Ikle D; Tchao NK; Ding L; Brunetta P; Choi HK; Monach PA; Fervenza F; Stone JH; Specks U;
    Ann Rheum Dis; 2016 Jun; 75(6):1166-9. PubMed ID: 26621483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis.
    Berti A; Warner R; Johnson K; Cornec D; Schroeder DR; Kabat BF; Langford CA; Kallenberg CGM; Seo P; Spiera RF; St Clair EW; Fervenza FC; Stone JH; Monach PA; Specks U; Merkel PA;
    J Autoimmun; 2019 Dec; 105():102302. PubMed ID: 31320177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinction between MPO-ANCA and PR3-ANCA-associated glomerulonephritis in Chinese patients: a retrospective single-center study.
    Hong Y; Shi P; Liu X; Yang L; Li K; Xu F; Liang S; Liu Z; Zhang H; Chen Y; Hu W
    Clin Rheumatol; 2019 Jun; 38(6):1665-1673. PubMed ID: 30737591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolonged infections associated with antineutrophil cytoplasmic antibodies specific to proteinase 3 and myeloperoxidase: diagnostic and therapeutic challenge.
    Bonaci-Nikolic B; Andrejevic S; Pavlovic M; Dimcic Z; Ivanovic B; Nikolic M
    Clin Rheumatol; 2010 Aug; 29(8):893-904. PubMed ID: 20306213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial.
    Sanders JS; de Joode AA; DeSevaux RG; Broekroelofs J; Voskuyl AE; van Paassen P; Kallenberg CG; Tervaert JW; Stegeman CA
    Nephrol Dial Transplant; 2016 Sep; 31(9):1453-9. PubMed ID: 27242368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.